[go: up one dir, main page]

NO20073101L - Nye pyridinforbindelser - Google Patents

Nye pyridinforbindelser

Info

Publication number
NO20073101L
NO20073101L NO20073101A NO20073101A NO20073101L NO 20073101 L NO20073101 L NO 20073101L NO 20073101 A NO20073101 A NO 20073101A NO 20073101 A NO20073101 A NO 20073101A NO 20073101 L NO20073101 L NO 20073101L
Authority
NO
Norway
Prior art keywords
pyridine compounds
new pyridine
compounds
processes
preparation
Prior art date
Application number
NO20073101A
Other languages
English (en)
Inventor
Robert D Groneberg
Kay Brickmann
Leifeng Cheng
Jonas Bostrom
Fabrizio Giordanetto
Peter Bach
Darren Martin Harvey
Michael F O'sullivan
Fredrik Zetterberg
Krister Osterlund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500140A external-priority patent/GB0500140D0/en
Priority claimed from GB0521484A external-priority patent/GB0521484D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073101L publication Critical patent/NO20073101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår visse nye pyridin-forbindelser med formel (I), fremgangsmåter for fremstilling av slike forbindelser, deres nytte som P2Y12-inhibitorer og som anti-trombotiske midler etc og fremgangsmåter for fremstilling av dem, anvendelse av dem som medikamenter ved kardiovaskulære sykdommer så vel som farmasøytiske preparater inneholdende dem.
NO20073101A 2005-01-06 2007-06-18 Nye pyridinforbindelser NO20073101L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0500140A GB0500140D0 (en) 2005-01-06 2005-01-06 Novel compounds
GB0521484A GB0521484D0 (en) 2005-10-21 2005-10-21 Novel compounds
PCT/SE2006/000010 WO2006073361A1 (en) 2005-01-06 2006-01-04 Novel pyridine compounds

Publications (1)

Publication Number Publication Date
NO20073101L true NO20073101L (no) 2007-07-19

Family

ID=36647772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073101A NO20073101L (no) 2005-01-06 2007-06-18 Nye pyridinforbindelser

Country Status (15)

Country Link
US (1) US20090227555A2 (no)
EP (1) EP1836189A1 (no)
JP (1) JP2008526840A (no)
KR (1) KR20070107024A (no)
AR (1) AR055554A1 (no)
AU (1) AU2006204159A1 (no)
BR (1) BRPI0606437A (no)
CA (1) CA2594255A1 (no)
IL (1) IL183961A0 (no)
MX (1) MX2007008237A (no)
NO (1) NO20073101L (no)
RU (1) RU2007129779A (no)
TW (1) TW200626593A (no)
UY (1) UY29325A1 (no)
WO (1) WO2006073361A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008000470A (es) * 2005-07-13 2008-03-11 Astrazeneca Ab Analogos de piridina nuevos.
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
MX2008016557A (es) * 2006-07-04 2009-02-06 Astrazeneca Ab Analogos de piridina nuevos.
WO2008004944A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline form ii
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
WO2008004945A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline forms i and ii
WO2008085119A1 (en) * 2007-01-12 2008-07-17 Astrazeneca Ab New pyridine analogues viii 518
WO2008085117A1 (en) * 2007-01-12 2008-07-17 Astrazeneca Ab Pyridine compounds and their use as p2y12 antagonists.
AR064864A1 (es) * 2007-01-12 2009-04-29 Astrazeneca Ab Compuestos analogos de piridina vii 543 y composicion farmaceutica
WO2008155022A1 (en) * 2007-06-18 2008-12-24 Sanofi-Aventis Pyrrole derivatives as p2y12 antagonists
CL2008000090A1 (es) * 2007-07-13 2009-01-16 Astrazeneca Ab Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas.
WO2010005385A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab 2-amino-6-alkyl substituted pyridine derivatives useful as p2y12 inhibitors 308
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
IN2015DN00962A (no) 2012-08-21 2015-06-12 Hoffmann La Roche
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
AU2023388768A1 (en) 2022-12-06 2025-05-01 Idorsia Pharmaceuticals Ltd Crystalline adipic acid salt form of a ccr6 antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936089A (en) * 1995-05-29 1999-08-10 Pfizer Inc Dipeptides which promote release of growth hormone
AU9206798A (en) * 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
CA2400479C (en) * 2000-02-04 2010-10-05 Millennium Pharmaceuticals, Inc. Platelet adp receptor inhibitors
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
AR037097A1 (es) * 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
BRPI0512535A (pt) * 2004-06-24 2008-03-25 Incyte Corp compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
JP2009542643A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類似体
MX2008016557A (es) * 2006-07-04 2009-02-06 Astrazeneca Ab Analogos de piridina nuevos.

Also Published As

Publication number Publication date
AU2006204159A1 (en) 2006-07-13
UY29325A1 (es) 2006-08-31
RU2007129779A (ru) 2009-02-20
TW200626593A (en) 2006-08-01
AR055554A1 (es) 2007-08-22
JP2008526840A (ja) 2008-07-24
US20090227555A2 (en) 2009-09-10
WO2006073361A1 (en) 2006-07-13
BRPI0606437A (pt) 2008-03-11
CA2594255A1 (en) 2006-07-13
IL183961A0 (en) 2007-10-31
US20090042852A1 (en) 2009-02-12
EP1836189A1 (en) 2007-09-26
MX2007008237A (es) 2007-08-17
KR20070107024A (ko) 2007-11-06
WO2006073361A9 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
NO20073101L (no) Nye pyridinforbindelser
NO20085218L (no) Nye pyridinanaloger
NO20076682L (no) Nye pyridinanaloger
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20085213L (no) Nye pyridinanaloger
NO20085214L (no) Nye pyridinanaloger
NO20071504L (no) Pyrimidinderivanter.
NO20085212L (no) Nye pyridinanaloger
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20082709L (no) Kjemiske forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20076648L (no) Novel thiophene derivatives
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20073719L (no) Kjemiske forbindelser
TW200732323A (en) Organic compounds
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20090328L (no) Nye forbindelser 385
TNSN07075A1 (en) Pyrimidine derivatives
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20065946L (no) DPP-IV-inhibitorer
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application